Graham Fulford, founder of GFCT and GFCT Treatment Support, was diagnosed with prostate cancer early this year. An update from Graham: You may remember from my last update that following the Prostatype report, the next leg was a flow test and bladder scan. The good news on the first part is that "it is a very impressive flow pattern with a maximum flow of 35m/s and a perfect curve". The not quite so good news is that the bladder scan indicated that whilst I man...

At GFCT Treatment Support, we are committed to advancing the availability of all prostate cancer treatments, especially focal therapies such as High Intensity Focused Ultrasound (HIFU). These minimally invasive treatments can be life-changing for thousands of men each year, offering effective cancer control with significantly reduced side effects compared to radical surgery or radiotherapy. Through our work, we’re supporting NHS hospitals by helping equip them with the technology need...

We recently changed our name from GFCT Focal Therapy Ltd to GFCT Treatment Support Ltd to better reflect our broader commitment to supporting all prostate cancer treatment options and helping ease pressure points in the healthcare system. A recent example is our donation of an ultrasound machine to Scunthorpe General Hospital, enabling the launch of two new one-stop clinics for prostate cancer treatment across Humberside and Lincolnshire. This initiative is already ...

Our founder, Graham Fulford MBE, travelled to Scunthorpe General Hospital on Friday 4th July 2025 to present a donated ultrasound machine to the assembled urology team: "It is a privilege to be working with Lead Consultant Urologist, Israr Khan, and his team. It is a real pleasure to be able to make this presentation to help the urology department in it's ongoing battle to diagnose more men with prostate cancer at an earlier stage, thereby improving the patient's chances o...

We're delighted to announce that we are sponsoring a charity stand at the BAUN Annual Conference in Edinburgh this November. Urological nurses play a vital and growing role in the prostate cancer diagnosis pathway - taking on advanced procedures such as biopsies, supporting patients throughout their treatment, and driving improvements in care. We’re proud to support them at this important event. The British Association of Urological Nurses (BAUN) is the UK’s leading org...

As you may be aware, this wholly owned subsidiary of GFCT, was formed to promote, amongst other things, the range of focal therapies which carry many potential advantages for men who have been newly diagnosed with prostate cancer. Whilst this remains central to its aims and ambitions, it's becoming increasingly obvious to us that because of the huge pressures within the NHS, the pathway to diagnosis itself can be fraught with difficulties and delays. In order to help alleviate...

Graham Fulford, founder of GFCT and GFCT Focal Therapy, was diagnosed with prostate cancer early this year. An update from Graham: My Personal Journey Continues Dear all, I mentioned in my last update that I was having a Prostatype test as part of my ongoing active surveillance and I can report that the results are now in. They indicate that I'm at low risk of mortality from prostate cancer in the next 10 years - so it's off to the pub to celebrate...

An exciting update on our project... From Graham Fulford, founder of GFCT Focal Therapy: "I'm delighted to inform you that we've now raised a total of £352,000 through a combination of donations and loans. We are now in position to fund the first of our target of helping three NHS hospitals to offer life changing HIFU treatment for prostate cancer! A huge thank you to all of our supporters. We're working very hard with a number of hospita...

Paul Sayer on "Curing with Sound" podcast by the Focused Ultrasound Foundation—an enlightening listen. Summary of the episode by Focused Ultrasound Foundation: In this episode of Curing with Sound, we hear from Paul Sayer, a prostate cancer survivor from the United Kingdom, whose life was transformed by focused ultrasound treatment. Diagnosed with aggressive prostate cancer in 2018 and initially advised to undergo surgery, Paul took the initiative to research alter...

Graham Fulford, founder of GFCT and GFCT Focal Therapy, was diagnosed with prostate cancer early this year. An update from Graham:  I have now received the results of my most recent PSA test, which has come back at 3.44, slightly lower than my previous result. Barring any unexpected findings from the outstanding Prostatype test, I will proceed with the next PSA test in September, followed by an MRI scan in October. Encouraging news, as you might agree! Interestingly...